Latest Insider Transactions at Akebia Therapeutics, Inc. (AKBA)
This section provides a real-time view of insider transactions for Akebia Therapeutics, Inc. (AKBA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akebia Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akebia Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Nicholas Grund Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
55,621
-11.16%
|
$111,242
$2.1 P/Share
|
|
Feb 03
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
30,202
-9.73%
|
$60,404
$2.1 P/Share
|
|
Feb 03
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,506
-2.96%
|
$101,012
$2.1 P/Share
|
|
Feb 03
2025
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
144,250
-2.65%
|
$288,500
$2.1 P/Share
|
|
Jan 31
2025
|
Nicholas Grund Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+28.12%
|
-
|
|
Jan 31
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+21.49%
|
-
|
|
Jan 31
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+18.36%
|
-
|
|
Jan 31
2025
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
701,000
+20.32%
|
-
|
|
Jan 31
2025
|
Erik Ostrowski SVP, CFO, CBO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+26.35%
|
-
|
|
Jan 17
2025
|
Ron Frieson |
BUY
Exercise of conversion of derivative security
|
Direct |
20,100
+17.65%
|
$0
$0.45 P/Share
|
|
Jun 28
2024
|
Erik Ostrowski SVP, CFO, CBO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+50.0%
|
-
|
|
Jun 06
2024
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.33%
|
-
|
|
Jun 06
2024
|
Myles Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+23.5%
|
-
|
|
Jun 06
2024
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+15.4%
|
-
|
|
Jun 06
2024
|
Leanne M Zumwalt |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+28.93%
|
-
|
|
Jun 06
2024
|
Ron Frieson |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+28.93%
|
-
|
|
Jun 06
2024
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.39%
|
-
|
|
Jun 06
2024
|
Michael W Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.23%
|
-
|
|
May 13
2024
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
34,840
-4.93%
|
$34,840
$1.26 P/Share
|
|
May 13
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
12,016
-1.81%
|
$12,016
$1.26 P/Share
|
|
Feb 29
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,169
-1.02%
|
$7,169
$1.58 P/Share
|
|
Feb 29
2024
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
46,570
-2.23%
|
$46,570
$1.58 P/Share
|
|
Feb 29
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,974
-0.89%
|
$5,974
$1.58 P/Share
|
|
Feb 29
2024
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,661
-1.21%
|
$8,661
$1.58 P/Share
|
|
Feb 27
2024
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
37,733
-1.77%
|
$37,733
$1.52 P/Share
|
|
Feb 27
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,367
-1.18%
|
$8,367
$1.52 P/Share
|
|
Feb 27
2024
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,744
-1.48%
|
$10,744
$1.52 P/Share
|
|
Feb 27
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,411
-1.1%
|
$7,411
$1.52 P/Share
|
|
Feb 01
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
24,311
-3.3%
|
$24,311
$1.68 P/Share
|
|
Feb 01
2024
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
46,489
-2.14%
|
$46,489
$1.68 P/Share
|
|
Jan 31
2024
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
202,200
+21.56%
|
-
|
|
Jan 31
2024
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
603,500
+21.72%
|
-
|
|
Jan 31
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
149,300
+18.08%
|
-
|
|
Jan 31
2024
|
Ellen Snow SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
149,300
+22.33%
|
-
|
|
Jan 31
2024
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
149,300
+17.05%
|
-
|
|
Jan 31
2024
|
Richard C Malabre SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
223,950
+50.0%
|
-
|
|
Jan 31
2024
|
Nicholas Grund Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
303,300
+50.0%
|
-
|
|
Aug 25
2023
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
27,000
-3.88%
|
$27,000
$1.15 P/Share
|
|
Jul 31
2023
|
Ellen Snow SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
370,000
+50.0%
|
-
|
|
Jun 06
2023
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.61%
|
-
|
|
Jun 06
2023
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+23.96%
|
-
|
|
Jun 06
2023
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+18.2%
|
-
|
|
Jun 06
2023
|
Myles Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+30.71%
|
-
|
|
Jun 06
2023
|
Ron Frieson |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+40.71%
|
-
|
|
Jun 06
2023
|
Michael W Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+23.8%
|
-
|
|
Jun 06
2023
|
Leanne M Zumwalt |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+40.71%
|
-
|
|
May 25
2023
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
95,478
-14.26%
|
$95,478
$1.22 P/Share
|
|
May 25
2023
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
63,186
-10.75%
|
$63,186
$1.22 P/Share
|
|
May 24
2023
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+23.0%
|
-
|
|
May 24
2023
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+25.4%
|
-
|